Merck has announced that it is launching a clinical trial to evaluate whether its integrase inhibitor, Isentress (raltegravir), can be used once daily by people who’ve never taken antiretroviral (ARV) therapy.
Isentress, which stops HIV from integrating into the genetic material of CD4 cells, is currently approved for people who are heavily treatment experienced and is taken twice a day.
The new trial, called QDMRK, will enroll 750 HIV-positive patients in 21 countries who’ve never taken ARV treatment. It will compare a regimen containing 400 milligrams of Isentress taken twice a day to a regimen containing 800 milligrams of Isentress once daily.
NEW! Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
"I am psychologically suffering from body wasting, mainly hips, face, legs and arms. Does anyone know where I can order something (maybe underwear with foam) to fill the sunken hips, so that pants can start looking normal? I feel pathetic when I look at myself in the mirror in jeans—jeans used to fill up so nicely, now they just hang!"
